Gregory Napolitano
New Baltimore, MINPI 1871140533
Payments from drug & device makers
Across 132 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$556
- Alkermes, Inc.$289
- Otsuka America Pharmaceutical, Inc.$217
- Corium, LLC$200
- Tris Pharma Inc$171
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$153
- plus $853 from 16 others
What the payments were for
- Food & beverage$2,440100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 33 | $556 |
| Alkermes, Inc. | 15 | $289 |
| Otsuka America Pharmaceutical, Inc. | 12 | $217 |
| Corium, LLC | 11 | $200 |
| Tris Pharma Inc | 10 | $171 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $153 |
| Supernus Pharmaceuticals, Inc. | 7 | $126 |
| Lundbeck LLC | 6 | $117 |
| Neurocrine Biosciences, Inc. | 5 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $72 |
| Sunovion Pharmaceuticals Inc. | 4 | $68 |
| Noven Therapeutics, LLC | 4 | $63 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Validus Pharmaceuticals LLC | 2 | $40 |
| Indivior Inc. | 2 | $39 |
| Ironshore Pharmaceuticals Inc. | 2 | $36 |
| Sage Therapeutics, LLC | 1 | $35 |
| Harmony Biosciences LLC | 1 | $35 |
| Collegium Pharmaceutical, Inc. | 1 | $24 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 22 | $37,532 |
| VraylarCariprazine Hcl | 15 | $21,326 |
| TrintellixVortioxetine Hydrobromide | 26 | $13,582 |
| VyvanseLisdexamfetamine Dimesylate | 14 | $5,015 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 167 | $3,972 |
| Bupropion XlBupropion Hcl | 200 | $3,020 |
| Trazodone Hcl | 145 | $2,954 |
| Vilazodone Hcl | 17 | $2,728 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 33 | $2,476 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 59 | $2,123 |
| Buspirone Hcl | 106 | $2,120 |
| Paliperidone ErPaliperidone | 25 | $2,021 |
| Quetiapine Fumarate | 118 | $1,976 |
| Lorazepam | 119 | $1,765 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 24 | $1,765 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $217 | $37,53222 claims |
| AbbVieVraylar | $556 | $21,32615 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $72 | $18,59840 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Michiganon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.